[123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  2003-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1136/jnnp.74.3.294PMID 12588911PMCID PMC1738309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

  2002cited by this paper
• Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β-CIT SPECT study.

  2002cited by this paper
• Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study

  2002cited by this paper
• [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease

  2001cited by this paper
• In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

  2000cited by this paper
• [The Unified Parkinson's Disease Rating Scale].

  2000cited by this paper
• Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT

  2000cited by this paper
• Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism

  1999cited by this paper
• Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT

  1999cited by this paper
• Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F] dopa PET

  1999cited by this paper
• Comparison between the decrease of dopamine transporter and that of L‐DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models

  1999cited by this paper
• The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease

  1999cited by this paper
• Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET

  1998cited by this paper
• Dystonia with motor delay in compound heterozygotes for GTP‐cyclohydrolase I gene mutations

  1998cited by this paper
• The early diagnosis of parkinson's disease

  1998cited by this paper
• Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.

  1998cited by this paper
• [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

  1997cited by this paper
• Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats

  1997cited by this paper
• [123I]β-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls

  1997cited by this paper
• Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT

  1997cited by this paper
• [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease

  1997cited by this paper
• Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.

  1997cited by this paper
• Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites.

  1996cited by this paper
• An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

  1996cited by this paper
• Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT.

  1995cited by this paper
• Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease

  1995cited by this paper
• Age-Related Decline in Striatal Dopamine Transporter Binding with Iodine-123-β-CITSPECT

  1995cited by this paper
• The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.

  1995cited by this paper
• Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

  1994cited by this paper
• Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects

  1994cited by this paper
• SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates

  1993cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine‐123 labeled RTI‐55

  1992cited by this paper
• Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's‐diseased striatum

  1991cited by this paper
• Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.

  1990cited by this paper
• Practical statistics for medical research

  1990cited by this paper
• Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale

  1987cited by this paper
• Recent Developments in Parkinson's Disease

  1986cited by this paper
• The early diagnosis of Parkinson's disease.

  1984cited by this paper
• Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

  1973cited by this paper
• Parkinsonism

  1967cited by this paper

• Key contemporary considerations for halogens in drug discovery.

  2026cites this paper
• Highlights on U.S. FDA-approved halogen-containing drugs in 2024.

  2025cites this paper
• Reduction in variability of dopamine transporter measures using SPECT and ultra-high-resolution fan beam collimators: comparison with parallel-hole collimators in healthy controls for a clinical reference database

  2024cites this paper
• A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice

  2023cites this paper
• Neuroprotective Effects of Cerebroprotein Hydrolysate on MPTP-induced Parkinson's Mice by Increasing Neurotrophin and Regulating Intestinal Microbiota

  2023cites this paper
• Effects of medication on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice

  2023cites this paper
• Motor Progression and Nigrostriatal Neurodegeneration in Parkinson Disease

  2022cites this paper
• Serial DaT‐SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years’ follow‐up

  2021cites this paper
• Glucuronomannan GM2 from Saccharina japonica Enhanced Mitochondrial Function and Autophagy in a Parkinson’s Model

  2021cites this paper
• The role of neuroimaging in Parkinson’s disease

  2021cites this paper
• Increased activation of the caudate nucleus and parahippocampal gyrus in Parkinson's disease patients with dysphagia after repetitive transcranial magnetic stimulation: a case-control study

  2021cites this paper
• Personalized Healthcare for Dementia

  2021cites this paper
• Simplified quantification of [18F]FE-PE2I PET in Parkinson’s disease: Discriminative power, test–retest reliability and longitudinal validity during early peak and late pseudo-equilibrium

  2020cites this paper
• Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease

  2020cites this paper
• Use of radioiodine in nuclear medicine a - brief overview.

  2020cites this paper
• A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index

  2020cites this paper
• Diagnostic Performance of 123I-FPCIT SPECT Specific Binding Ratio in Progressive Supranuclear Palsy: Use of Core Clinical Features and MRI for Comparison.

  2020cites this paper
• Preparation and Neuroprotective Activity of Glucuronomannan Oligosaccharides in an MPTP-Induced Parkinson’s Model

  2020cites this paper
• Dopamine Transporter Imaging in Parkinson Disease: Progressive Changes and Therapeutic Modification after Anti-parkinsonian Medications

  2019cites this paper
• Clinical implications of early caudate dysfunction in Parkinson’s disease

  2019cites this paper
• Drug Augmentation Strategies for Treatment-Resistant Obsessive-Compulsive and Related Disorders

  2019cites this paper
• Advances in SPECT Methodology.

  2018cites this paper
• Can early dopamine transporter imaging serve as a predictor of Parkinson's disease progression and late motor complications?

  2018cites this paper
• Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease

  2017cites this paper
• Imaging in Parkinson's Disease.

  2017cites this paper
• Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

  2017cites this paper
• Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.

  2016cites this paper
• Neurorescue by a ROS Decomposition Catalyst.

  2016cites this paper
• Imaging of Neurotransmitter Systems in Dementia

  2016cites this paper
• Parkinsonism and Related Disorders

  2016cites this paper
• Intensity normalization of DaTSCAN SPECT imaging using a model-based clustering approach

  2015cites this paper
• Analysis of 18F-DMFP PET data using multikernel classification in order to assist the diagnosis of Parkinsonism

  2015cites this paper
• Role of dopaminergic neurotransmission in pathophysiology of action tremor in Parkinson's disease.

  2015cites this paper
• Building a FP-CIT SPECT Brain Template Using a Posterization Approach

  2015cites this paper
• PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases.

  2015cites this paper
• Distinguishing Parkinson's disease from atypical parkinsonian syndromes using PET data and a computer system based on support vector machines and Bayesian networks

  2015cites this paper
• Familial Hemiplegic Migraine Type 1 Associated with Parkinsonism: A Case Report

  2015cites this paper
• Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.

  2015cites this paper
• Human Brain Imaging of Dopamine Transporters

  2014cites this paper
• Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan)

  2014cites this paper
• Meta-cognitive sequential learning in RBF network for diagnosis of neurodegenerative diseases

  2014cites this paper
• Automatic detection of Parkinsonism using significance measures and component analysis in DaTSCAN imaging

  2014cites this paper
• Neuroprotective Effects of Jitai Tablet, a Traditional Chinese Medicine, on the MPTP-Induced Acute Model of Parkinson's Disease: Involvement of the Dopamine System

  2014cites this paper
• A novel PBL-McRBFN-RFE approach for identification of critical brain regions responsible for Parkinson's disease

  2014cites this paper
• Application of Empirical Mode Decomposition (EMD) on DaTSCAN SPECT images to explore Parkinson Disease

  2013cites this paper
• Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry

  2013cites this paper
• Performance of a high-sensitivity dedicated cardiac SPECT scanner for striatal uptake quantification in the brain based on analysis of projection data.

  2013cites this paper
• Cardiac sympathetic denervation in Parkinson’s disease patients with SWEDDs

  2013cites this paper
• Parametrization of textural patterns in 123I-ioflupane imaging for the automatic detection of Parkinsonism.

  2013cites this paper
• A one-step fully automated radio-synthesis of a dopamine transporter PET imaging agent 18F-FECNT and its in vivo evaluations

  2013cites this paper
• Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease.

  2012cites this paper
• Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients

  2012cites this paper
• Parkinson Subtypes Progress Differently in Clinical Course and Imaging Pattern

  2012cites this paper
• Improved Parkinsonism diagnosis using a partial least squares based approach.

  2012cites this paper
• SPECT Molecular Imaging in Parkinson's Disease

  2012cites this paper
• Gene Therapy for Parkinson’s: Disease from Bench to Bedside

  2012cites this paper
• Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.

  2011cites this paper
• Sequential imaging analysis using MIBG scintigraphy revealed progressive degeneration of cardiac sympathetic nerve in Parkinson’s disease

  2011cites this paper
• Can nicotine be used medicinally in Parkinson’s disease?

  2011cites this paper
• Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.

  2011cites this paper
• A New Technological Fusion of PET and MRI for Brain Imaging

  2011cites this paper
• Development of Parkinson’s disease biomarkers

  2010cites this paper
• PET and SPECT

  2010cites this paper
• Extrapyramidal syndromes: PET and SPECT.

  2010cites this paper
• De rol van presynaptische dopaminerge beeldvorming bij de ziekte van Parkinson

  2010cites this paper
• Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease

  2009cites this paper
• Progression of Parkinson's disease in the clinical phase: potential markers.

  2009cites this paper
• Neuroprotection and imaging studies in Parkinson's disease.

  2009cites this paper
• Imaging neurodegeneration in Parkinson's disease.

  2009cites this paper
• Transcranial duplex scanning in parkinsonian disorders : comparison with SPECT

  2009cites this paper
• [123I]-FP-CIT SPECT and olfaction test in patients with combined postural and rest tremor

  2008cites this paper
• An expert opinion on safinamide in Parkinson's disease.

  2008cites this paper
• Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs

  2008cites this paper
• An expert opinion on safinamide in Parkinson's disease

  2008cites this paper
• An expert opinion on safi namide in Parkinson's disease

  2008cites this paper
• Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson’s disease

  2007cites this paper
• Influence of movement on FP-CIT SPECT quantification: a Monte Carlo based simulation

  2007cites this paper
• Parkinson's disease: monitoring early diagnosis and disease progression

  2007influential citation
• Investigating the Dopaminergic Synapse In Vivo. I. Molecular Imaging Studies in Humans

  2007cites this paper
• One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system.

  2007cites this paper
• SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.

  2007cites this paper
• SPECT disclose complementary aspects of Parkinson's disease

  2006cites this paper
• Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease.

  2006cites this paper
• Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease

  2006cites this paper
• The Design and Manufacture of an Annular Variable-Focusing Collimator for Highsensitivity Brain SPECT

  2006cites this paper
• A View on Early Diagnosis of Dementias from Neuropathology

  2006cites this paper
• Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging

  2006cites this paper
• Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease.

  2005cites this paper
• 123-I ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients with movement disorders

  2005influential citation
• Brain SPECT with short focal-length cone-beam collimation.

  2005cites this paper
• [Advantages and limitations in the assessment of neuroprotective treatment of Parkinson's disease by functional imaging].

  2005cites this paper
• [Dopaminergic neurotransmission image in Parkinsonian syndromes].

  2005cites this paper
• Contribution et limites de l’imagerie fonctionnelle dans l’évaluation des traitements à visée neuroprotectrice dans la maladie de Parkinson

  2005cites this paper
• FP‐CIT and MIBG scintigraphy in early Parkinson's disease

  2005cites this paper
• Brain SPECT with short focal-length cone-beam collimation.

  2005cites this paper
• Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT

  2005cites this paper
• Imagen de neurotransmisión dopaminérgica en los síndromes parkinsonianos

  2005cites this paper
• The sensitivity of 18‐fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease

  2004cites this paper
• Comparison of α-dihydroergocryptine and levodopa monotherapy in Parkinson’s disease: assessment of changes in DAT binding with [123I]IPT SPECT

  2004cites this paper
• Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-β-CIT versus 99mTc-TRODAT-1

  2004cites this paper